Evidence map›Paper›PMID 32453766›Full record

ArticlePloS one2020

Computational model of tranexamic acid on urokinase mediated fibrinolysis.

Tie Bo Wu, Thomas Orfeo, Hunter B Moore, Joshua J Sumislawski, Mitchell J Cohen, Linda R Petzold

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. A breath of fresh air: an updated review of nebulised tranexamic acid for post-tonsillectomy haemorrhage.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Chemical Adjustment of Fibrinolysis.Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Tie Bo WuDepartment of Mechanical Engineering, University of California Santa Barbara, Santa Barbara, California, United States of America.ORCID 0000-0001-9522-3626
Thomas OrfeoDepartment of Biochemistry, University of Vermont, Burlington, Vermont, United States of America.
Hunter B MooreDepartment of Surgery, Denver Health and Hospital Authority, Denver, Colorado, United States of America.
Joshua J SumislawskiDepartment of Surgery, Denver Health and Hospital Authority, Denver, Colorado, United States of America.
Mitchell J CohenDepartment of Surgery, Denver Health and Hospital Authority, Denver, Colorado, United States of America.
Linda R PetzoldDepartment of Mechanical Engineering, University of California Santa Barbara, Santa Barbara, California, United States of America.ORCID 0000-0001-6251-6078
Denver Health Medical Center · USUniversity of California, Santa Barbara · USUniversity of Vermont · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding the coagulation process is critical to developing treatments for trauma and coagulopathies. Clinical studies on tranexamic acid (TXA) have resulted in mixed reports on its efficacy in improving outcomes in trauma patients. The largest study, CRASH-2, reported that TXA improved outcomes in patients who received treatment prior to 3 hours after the injury, but worsened outcomes in patients who received treatment after 3 hours. No consensus has been reached about the mechanism behind the duality of these results. In this paper we use a computational model for coagulation and fibrinolysis to propose that deficiencies or depletions of key anti-fibrinolytic proteins, specifically antiplasmin, a1-antitrypsin and a2-macroglobulin, can lead to worsened outcomes through urokinase-mediated hyperfibrinolysis.

Indexed as

alpha 1-AntitrypsinAntifibrinolytic AgentsBlood CoagulationBlood Coagulation DisordersComputer SimulationFibrinFibrin Clot Lysis TimeFibrinolysinFibrinolysisHemorrhageHumansMembrane ProteinsMortalityPregnancy-Associated alpha 2-MacroglobulinsThrombinTranexamic Acidalpha 1-AntitrypsinAntifibrinolytic AgentsFibrinFibrinolysinMembrane ProteinsPLAU protein, humanPregnancy-Associated alpha 2-MacroglobulinsThrombinTranexamic AcidUrokinase-Type Plasminogen Activator

Identifiers

PMID32453766
PMCPMC7250412
OpenAlexW3032797196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.